NovoCure Surpasses Q1 Expectations

NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates. NovoCure (NVCR 7.34%), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street's estimate of $146 million. The first quarter was marked by considerable revenue growth for NovoCure. GAAP revenue reached $155 ...